By Professor Jason Grebely

Journal articles

Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L; Peacock A, 2017, 'Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review', The Lancet Global Health, 5, pp. e1208 - e1220, http://dx.doi.org/10.1016/S2214-109X(17)30373-X

Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025

Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106

Larney S; Hickman M; Guy R; Grebely J; Dore GJ; Gray RT; Day CA; Kimber J; Degenhardt L, 2017, 'Estimating the number of people who inject drugs in Australia', BMC Public Health, 17, pp. 757, http://dx.doi.org/10.1186/s12889-017-4785-7

Marshall AD; Grebely J; Dore GJ; Treloar C, 2017, '‘I didn't want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study', International Journal of Drug Policy, 47, pp. 153 - 160, http://dx.doi.org/10.1016/j.drugpo.2017.06.001

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Grebely J; Bruneau J; Bruggmann P; Harris M; Hickman M; Rhodes T; Treloar C, 2017, 'Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy', International Journal of Drug Policy, 47, pp. 26 - 33, http://dx.doi.org/10.1016/j.drugpo.2017.08.001

Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L, 2017, 'Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia', International Journal of Drug Policy, 47, pp. 77 - 85, http://dx.doi.org/10.1016/j.drugpo.2017.05.022

Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002

Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701

Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ, 2017, 'Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs', International Journal of Drug Policy, 47, pp. 51 - 60, http://dx.doi.org/10.1016/j.drugpo.2017.05.019

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007

Hickman M; Grebely J; Bruneau J; Coffin P; Degenhardt L; Hutchinson S; Larney S; Martin N; Treloar C; Vickerman P, 2017, 'New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs—announcing an Addiction series', Addiction, 112, pp. 1126 - 1127, http://dx.doi.org/10.1111/add.13847

Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, 17, pp. 420, http://dx.doi.org/10.1186/s12879-017-2517-3

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8

Bartlett SR; Wertheim JO; Bull RA; Matthews GV; Lamoury FMJ; Scheffler K; Hellard M; Maher L; Dore GJ; Lloyd AR; Applegate TL; Grebely J, 2017, 'A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies', Journal of Viral Hepatitis, 24, pp. 404 - 411, http://dx.doi.org/10.1111/jvh.12652

Martinello M; Grebely J; Matthews GV, 2017, 'Direct-acting antivirals for acute HCV: how short can we go?', The Lancet Gastroenterology and Hepatology, 2, pp. 316 - 318, http://dx.doi.org/10.1016/S2468-1253(17)30043-2

Martinello M; Grebely J; Petoumenos K; Gane E; Hellard M; Shaw D; Sasadeusz J; Applegate TL; Dore GJ; Matthews GV, 2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, 24, pp. 359 - 370, http://dx.doi.org/10.1111/jvh.12666

Eslam M; McLeod D; Kelaeng KS; Mangia A; Berg T; Thabet K; Irving WL; Dore GJ; Sheridan D; Grønbæk H; Abate ML; Hartmann R; Bugianesi E; Spengler U; Rojas A; Booth DR; Weltman M; Mollison L; Cheng W; Riordan S; Mahajan H; Fischer J; Nattermann J; Douglas MW; Liddle C; Powell E; Romero-Gomez M; George J; Metwally M; White R; Gallego-Duran R; Leung R; Mahajan N; Bassendine M; Rahme A; Rosso C; Mezzabotta L; Malik B; Matthews G; Asimakopoulos A; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santoro R, 2017, 'IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis', Nature Genetics, 49, pp. 795 - 800, http://dx.doi.org/10.1038/ng.3836

Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K, 2017, 'Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration', Clinical Infectious Diseases, 64, pp. 860 - 869, http://dx.doi.org/10.1093/cid/ciw869

Haber B; Gane E; Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'HEPATITIS C VIRUS (HCV) REINFECTION AND INJECTION RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS ON OPIOID AGONIST THERAPY (OAT): CO-STAR THREE-YEAR FOLLOW-UP STUDY', GASTROENTEROLOGY, 152, pp. S1058 - S1059, http://dx.doi.org/10.1016/S0016-5085(17)33575-8

Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA, 2017, 'Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection', Infection, Genetics and Evolution, 49, pp. 88 - 96, http://dx.doi.org/10.1016/j.meegid.2017.01.006

Grebely J; Dore GJ, 2017, 'Treatment of HCV in persons who inject drugs: Treatment as prevention', Clinical Liver Disease, 9, pp. 77 - 80, http://dx.doi.org/10.1002/cld.626

Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F; Abaalkhail F; Abdou A; Abdulla M; Abou Rached A; Aho I; Akarca U; Al Ghazzawi I; Al Kaabi S; Al Lawati F; Al Namaani K; Al Serkal Y; Al-Busafi SA; Al-Dabal L; Aleman S; Alghamdi AS; Aljumah AA; Al-Romaihi HE; Andersson MI; Arendt V; Arkkila P; Assiri AM; Baatarkhuu O; Bane A; Ben-Ari Z; Bergin C; Bessone F; Bihl F; Bizri AR; Blachier M; Blasco AJ; Brandao Mello CE; Bruggmann P; Brunton CR; Calinas F; Chan HLY; Chaudhry A; Cheinquer H; Chen CJ; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Cisneros L; Clausen MR; Cramp ME; Craxi A; Croes EA; Dalgard O; Daruich JR; De Ledinghen V; Dore GJ; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Farag E; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gamkrelidze I; Gane E; Garcia-Samaniego J; Khan AG; Gountas I; Goldis A; Gottfredsson M; Grebely J; Gschwantler M; Guimaraes Pessoa M; Gunter J; Hajarizadeh B; Hajelssedig O; Hamid S; Hamoudi W; Hatzakis A; Himatt SM; Hofer H; Hrstic I; Hui YT; Hunyady B; Idilman R; Jafri W; Jahis R; Janjua NZ; Jarčuška P; Jeruma A; Jonasson JG, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study', The Lancet Gastroenterology and Hepatology, 2, pp. 161 - 176, http://dx.doi.org/10.1016/S2468-1253(16)30181-9

Eltahla AA; Leung P; Pirozyan MR; Rodrigo C; Grebely J; Applegate T; Maher L; Luciani F; Lloyd AR; Bull RA, 2017, 'Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment', Scientific Reports, 7, pp. 41719, http://dx.doi.org/10.1038/srep41719

Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA, 2017, 'Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents', Journal of Viral Hepatitis, 24, pp. 37 - 42, http://dx.doi.org/10.1111/jvh.12615

Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453

Fortier E; Alavi M; Bruneau J; Micallef M; Perram J; Sockalingam S; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2017, 'Depression, Anxiety, and Stress among People with Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia', Journal of Addiction Medicine, 11, pp. 10 - 18, http://dx.doi.org/10.1097/adm.0000000000000261

Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB, 2017, 'Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there', Journal of the International AIDS Society, 20, pp. 22146, http://dx.doi.org/10.7448/IAS.20.1.22146

Rodrigo C; Eltahla AA; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Lloyd AR, 2017, 'Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC³ Study', Journal of Viral Hepatitis, 24, pp. 43 - 52, http://dx.doi.org/10.1111/jvh.12616

Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe AYM; Miller V; Ceccherini-Silberstein F; Bull RA; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky JM; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review', Hepatology Communications, 1, pp. 379 - 390, http://dx.doi.org/10.1002/hep4.1050

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014)', Hepatology Communications, 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Hepatology, 66, pp. S513 - S513, http://dx.doi.org/10.1016/s0168-8278(17)31428-9

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Virus Eradication, 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30896-7

Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Iser DM; Huang HC; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study', Journal of Virus Eradication, 3, pp. 8 - 8, http://dx.doi.org/10.1016/s2055-6640(20)30904-3

Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, 3, pp. 9 - 9, http://dx.doi.org/10.1016/s2055-6640(20)30906-7

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study', Journal of Virus Eradication, 3, pp. 2 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30889-x

Iversen J; Grebely J; Catlett B; Cunningham P; Dore GD; Maher L, 2017, 'O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies', Journal of Virus Eradication, 3, pp. 4 - 4, http://dx.doi.org/10.1016/s2055-6640(20)30892-x

Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, 3, pp. 19 - 19, http://dx.doi.org/10.1016/s2055-6640(20)30761-5

Bajis S; Lamoury F; Applegate TL; Maher L; Treloar C; Mowat Y; Schulz M; Hajarizadeh B; Marshall A; Cunningham E; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Dore GJ; Grebely J, 2017, 'P4 Acceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people', Journal of Virus Eradication, 3, pp. 13 - 14, http://dx.doi.org/10.1016/s2055-6640(20)30745-7

Bartlett SR; Applegate T; Jacka B; Lamoury F; Bull R; Danta M; Bradshaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2017, 'P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015', Journal of Virus Eradication, 3, pp. 14 - 15, http://dx.doi.org/10.1016/s2055-6640(20)30747-0

Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', Journal of Hepatology, 66, pp. S513 - S514, http://dx.doi.org/10.1016/s0168-8278(17)31429-0

Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials', Clinical Infectious Diseases, 63, pp. 1405 - 1411, http://dx.doi.org/10.1093/cid/ciw580

Grebely J; Dore GJ; Zeuzem S; Aspinall RJ; Fox R; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Natha M; Foster GR; Mangia A; Sulkowski M; Feld JJ, 2016, 'Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials', Clinical Infectious Diseases, 63, pp. 1479 - 1481, http://dx.doi.org/10.1093/cid/ciw579

Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176

Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV; Cooper D, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844

Tsui JI; Mirzazadeh A; Hahn JA; Maher L; Bruneau J; Grebely J; Hellard M; Kim AY; Shoukry NH; Cox AL; Prins M; Dore GJ; Lauer G; Lloyd AR; Page K, 2016, 'The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males', Drug and Alcohol Dependence, 169, pp. 156 - 162, http://dx.doi.org/10.1016/j.drugalcdep.2016.10.024

Back to profile page